Novel statins: Pharmacological and clinical results

Chiara Bolego, Andrea Poli, Andrea Cignarella, Alberico L. Catapano, Rodolfo Paoletti

Research output: Contribution to journalArticle

Abstract

Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

Original languageEnglish
Pages (from-to)251-257
Number of pages7
JournalCardiovascular Drugs and Therapy
Volume16
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacology
Cholesterol
Mortality
Drug Interactions
Cytochrome P-450 Enzyme System
Myocardial Infarction
Morbidity
Incidence
Pharmaceutical Preparations
oxidized low density lipoprotein
pitavastatin
Rosuvastatin Calcium

Keywords

  • HMG-CoA reductase inhibitors
  • NK-140
  • Novel statins
  • Pitavastatin
  • Pleiotropic effects
  • Rosuvastatin
  • ZD 4522

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Novel statins : Pharmacological and clinical results. / Bolego, Chiara; Poli, Andrea; Cignarella, Andrea; Catapano, Alberico L.; Paoletti, Rodolfo.

In: Cardiovascular Drugs and Therapy, Vol. 16, No. 3, 2002, p. 251-257.

Research output: Contribution to journalArticle

Bolego, Chiara ; Poli, Andrea ; Cignarella, Andrea ; Catapano, Alberico L. ; Paoletti, Rodolfo. / Novel statins : Pharmacological and clinical results. In: Cardiovascular Drugs and Therapy. 2002 ; Vol. 16, No. 3. pp. 251-257.
@article{304c51d6283c467a9982419a3dbff320,
title = "Novel statins: Pharmacological and clinical results",
abstract = "Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.",
keywords = "HMG-CoA reductase inhibitors, NK-140, Novel statins, Pitavastatin, Pleiotropic effects, Rosuvastatin, ZD 4522",
author = "Chiara Bolego and Andrea Poli and Andrea Cignarella and Catapano, {Alberico L.} and Rodolfo Paoletti",
year = "2002",
doi = "10.1023/A:1020656607497",
language = "English",
volume = "16",
pages = "251--257",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Novel statins

T2 - Pharmacological and clinical results

AU - Bolego, Chiara

AU - Poli, Andrea

AU - Cignarella, Andrea

AU - Catapano, Alberico L.

AU - Paoletti, Rodolfo

PY - 2002

Y1 - 2002

N2 - Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

AB - Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

KW - HMG-CoA reductase inhibitors

KW - NK-140

KW - Novel statins

KW - Pitavastatin

KW - Pleiotropic effects

KW - Rosuvastatin

KW - ZD 4522

UR - http://www.scopus.com/inward/record.url?scp=0036437730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036437730&partnerID=8YFLogxK

U2 - 10.1023/A:1020656607497

DO - 10.1023/A:1020656607497

M3 - Article

C2 - 12374904

AN - SCOPUS:0036437730

VL - 16

SP - 251

EP - 257

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -